Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-029413
Filing Date
2024-03-11
Accepted
2024-03-11 17:12:21
Documents
83
Period of Report
2024-01-31

Document Format Files

Seq Description Document Type Size
1 10-Q engn-20240131.htm   iXBRL 10-Q 1606476
2 EX-31.1 engn-ex31_1.htm EX-31.1 18847
3 EX-31.2 engn-ex31_2.htm EX-31.2 18420
4 EX-32.1 engn-ex32_1.htm EX-32.1 9576
5 EX-32.2 engn-ex32_2.htm EX-32.2 9587
  Complete submission text file 0000950170-24-029413.txt   8669711

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT engn-20240131.xsd EX-101.SCH 1827901
85 EXTRACTED XBRL INSTANCE DOCUMENT engn-20240131_htm.xml XML 1118901
Mailing Address 4868 RUE LEVY, SUITE 220 SAINT-LAURENT A8 H4R 2P1
Business Address 4868 RUE LEVY, SUITE 220 SAINT-LAURENT A8 H4R 2P1 (514) 332-4888
enGene Holdings Inc. (Filer) CIK: 0001980845 (see all company filings)

EIN.: 000000000 | State of Incorp.: Z4 | Fiscal Year End: 1031
Type: 10-Q | Act: 34 | File No.: 001-41854 | Film No.: 24739074
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)